JoS

Rizos et al.   Low DOAC Exposure and Stroke Severity

Supplementary Table 5. Differences between low and high DOAC concentrations at onset of the event (n=179)

Variable	Low DOAC concentration (n=81, 45.3%)	High DOAC concentration (n=98, 54.7%)	Descriptive P
Female sex	43 (53.1)	51 (52.0)	0.889[†]
Age (yr)	78 (72–86)	81 (77–86)	0.019[‡]
Body weight (kg)	75 (68–85)	75 (65–83)	0.247[‡]
	75 (92.6)	94 (95.9)	
Ischemic stroke	69 (85.2)	62 (63.3)	0.001[†]
TIA	12 (14.8)	36 (36.7)	
Large vessel occlusion (ICA, MCA [1-3], PCA, ACA, BA)	33 (40.7)	37 (37.8)	0.684[†]
Time of ischemic stroke/TIA (00:00–7:59)	13 (16.0)	20 (20.4)	0.454[†]
Time of ischemic stroke/TIA (8:00–15:59)	49 (60.5)	45 (45.9)	0.052[†]
Time of ischemic stroke/TIA (16:00–23:59)	19 (23.5)	33 (33.7)	0.134[†]
Functional impairment			
Admission NIHSS of patients with ischemic stroke	8 (4–19)	9 (3–16)	0.755[‡]
Premorbid modified Rankin Scale	1 (0–3)	1 (0–3)	0.965[‡]
Modified Rankin Scale at 3 months	3 (1–6)	3 (1–5)	0.111[‡]
	74 (91.4)	96 (98.0)	
Comorbidities			
Arterial hypertension	73 (90.1)	86 (87.8)	0.617[†]
Diabetes	31 (38.3)	25 (25.5)	0.067[†]
Hypercholesterolemia	45 (55.6)	56 (57.1)	0.831[†]
Previous stroke or TIA	30 (37.0)	31 (31.6)	0.448[†]
Congestive heart failure	14 (17.3)	20 (20.4)	0.596[†]
Vascular disease	41 (50.6)	53 (54.1)	0.644[†]
Atrial fibrillation	73 (90.1)	90 (91.8)	0.689[†]
Premorbid CHA_2DS_2-VASc score	5 (4–6)	5 (4–6)	0.898[‡]
Creatinine at admission (mg/dL)	0.87 (0.75–1.12)	0.96 (0.80–1.14)	0.227[‡]
eGFR (mL/min)*	69.9 (52.7–86.8)	56.9 (44.0–78.4)	0.006[‡]
	75 (92.6)	92 (93.9)	
Pharmacotherapy			
Apixaban	23 (28.4)	44 (44.9)	0.023[†]
Edoxaban	11 (13.6)	5 (5.1)	0.048[†]
Rivaroxaban	35 (43.2)	43 (43.9)	0.929[†]
Dabigatran	12 (14.8)	6 (6.1)	0.054[†]
Additional antiplatelet therapy	10 (12.3)	9 (9.2)	0.541[†]
Time between last DOAC intake and admission (min)	895 (557–1,295)	507 (320–723)	<0.001[‡]
Time between DOAC intake and event (min)	660 (345–1,043)	383 (180–570)	<0.001[‡]
Prescription quality			
DOAC adherence to SmPCs: underdosed	25 (30.9)	21 (21.4)	0.150[†]
DOAC adherence to SmPCs: correctly dosed	54 (66.7)	72 (73.5)	0.321[†]
DOAC adherence to SmPCs: overdosed	2 (2.5)	5 (5.1)	0.366[†]

Values are presented as number (%) or median (interquartile range).
DOAC, direct oral anticoagulant; TIA, transient ischemic attack; ICA, internal carotid artery; MCA (1-3), middle cerebral artery (segments 1-3); PCA, posterior cerebral artery; ACA, anterior cerebral artery; BA, basilar artery; NIHSS, National Institutes of Health Stroke Scale; eGFR, estimated glomerular filtration rate; SmPC, recommended doses from summaries of product characteristic.
*eGFR according to Cockcroft-Gault formula; [†]Chi-square; [‡]t-test.